Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
TB Biosciences logo — Pioneering a new era in tuberculosis diagnostics with a rapi...

TB Biosciences

Pioneering a new era in tuberculosis diagnostics with a rapid, user-friendly test replacing century-old methods

Founded 2013 Series A Total: $1.50M Biotechnology, Health Care

General Information

Company Name TB Biosciences
Founded Year 2013
Founders / Decision Makers
Team member
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with TB Biosciences. To contact TB Biosciences, visit tbbiosciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does TB Biosciences compare?

A PDF of TB Biosciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting TB Biosciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About TB Biosciences

TB Biosciences, Inc. is a pioneering medical diagnostics company that was established in June 2013. The company operates in the biotechnology industry and is focused on developing a rapid point-of-care tuberculosis test. Their slogan, "Pioneering a new era in tuberculosis diagnostics with a rapid, user-friendly test replacing century-old methods," reflects their commitment to innovation in the field. The aim of TB Biosciences is to commercialize an easy-to-use tuberculosis test that serves as a modern alternative to the century-old sputum smear test. The company utilizes a variety of patented peptides, developed and exclusively licensed from the NYU School of Medicine. TB Biosciences received a $1.50M Series A investment at 18 July 2013 from NYU Innovation Venture Fund and Originate Ventures. This investment further supported the company's mission to revolutionize tuberculosis diagnostics. The company's innovative approach and strong backing from reputable investors position TB Biosciences as a key player in the development of advanced diagnostics for tuberculosis. With its focus on addressing a critical global health issue, TB Biosciences presents a promising opportunity for investors looking to support groundbreaking advancements in the biotechnology sector.

Business keywords: medical diagnostics, tuberculosis, point-of-care test, rapid test, patented peptides, NYU School of Medicine, diagnostic technology, biomedical research, disease detection, global health, medical innovation

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $1.50M 2
NYU Innovation Venture Fund Originate Ventures
NYU Innovation Venture Fund, Originate Ventures
18 Jul 2013

TB Biosciences Alternatives & Competitors

View All Alternatives
TB Biosciences vs
EMPE Diagnostics
EMPE Diagnostics Sweden

Confirmatory precision diagnostics for tuberculosis (MDR/XDR-TB) within 3 h even at resource-limited...

Series A
27 employees
Biotechnology, Health Care
TB Biosciences vs
Bilimetrix s.r.l.
Bilimetrix s.r.l. Italy

We dream of a world free from kernicterus, a preventable disabling condition, allowing newborns to e...

Seed
3 employees
Biotechnology, Health Care
TB Biosciences vs
Diagnostics Biochem Canada (DBC)
Diagnostics Biochem Canada (DBC) Canada

Develop and market unique immunoassay kits that make a difference in the field of diagnostics and in...

43 employees
Biotechnology, Health Care
View all alternatives

FAQ About TB Biosciences

Pioneering a new era in tuberculosis diagnostics with a rapid, user-friendly test replacing century-old methods
TB Biosciences was founded in 2013.
TB Biosciences operates in Biotechnology and Health Care. Its work centres on medical diagnostics, tuberculosis, point-of-care test and rapid test.
TB Biosciences has completed 1 funding round, raising a total of $1.50M. The latest funding stage is Series A.
Top alternatives and competitors to TB Biosciences include EMPE Diagnostics, Bilimetrix s.r.l., Diagnostics Biochem Canada (DBC), Microplate Dx Limited, Sanome. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
TB Biosciences and EMPE Diagnostics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for TB Biosciences, https://bouncewatch.com/company/tb-biosciences, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout